Año: 2020
Journal Impact Factor (JIF): 10.8490
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
CELL BIOLOGY | SCIE | 26/195 | Q1 | T1 | D2 |
Año: 2020
Journal Citation Indicator (JCI): 1,120
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
CELL BIOLOGY | 48/201 | Q1 | T1 | D3 | 76,37 |
Año:
2020
CiteScore:
12,100
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Biochemistry | 26/415 | Q1 | T1 | D1 |
Genetics | 23/325 | Q1 | T1 | D1 |
Cell Biology | 31/279 | Q1 | T1 | D2 |
Molecular Biology | 39/382 | Q1 | T1 | D2 |
SJR año:
2020
Factor de Impacto:
3,412
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Biochemistry | 19/467 | Q1 | T1 | D1 |
Cell Biology | 30/304 | Q1 | T1 | D1 |
Genetics | 23/364 | Q1 | T1 | D1 |
Molecular Biology | 39/434 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
NIH | CA192656; FD005113; GM135671; GM125195 |
Tower Cancer Research Foundation | - |
# | Autor | Afiliación |
---|---|---|
1 | Burgoyne, Adam M. | Moores Cancer Center (United States) |
2 | Vann, Kendra R. | University of Colorado School of Medicine (United States) |
3 | Joshi, Shweta | Moores Cancer Center (United States) |
4 | Morales, Guillermo A. | SignalRx Pharmaceuticals (United States) |
5 | Vega, Francisco M. | Universidad de Sevilla; Moores Cancer Center (United States) |
6 | Singh, Alok | Moores Cancer Center (United States) |
7 | Pal, Dhananjaya | Moores Cancer Center (United States) |
8 | Merati, Aran B. | Moores Cancer Center (United States) |
9 | University of Colorado School of Medicine (United States) | |
10 | Moores Cancer Center; SignalRx Pharmaceuticals (United States) |